Steve Kafka, PhD, is a Managing Partner of Section 32.
With a passion for working with exceptional scientists and creative business executives, Steve has built multiple companies with a focus on transforming and impacting patient care while creating exciting and rewarding professional opportunities for its employees.
Steve extends his medical technology expertise to several other ventures. He currently serves as the Executive Chairman for Thrive Earlier Detection, a biotechnology company that develops early detection tests for multiple types of cancer. Steve is also the Executive Chairman at the molecular technology company ArcherDX, Inc. which empowers physicians to apply high-quality genomics in daily clinical care.
Steve has held leadership roles with several pharmaceutical and biopharmaceutical companies, including Foundation Medicine, Aileron Therapeutics, and Infinity Pharmaceuticals.
Steve holds a PhD degree in political economy and government from Harvard University and a BA degree in economics and political science from Stanford University.